World Companion Diagnostics Summit (CDx Summit)
|Event Date/Time: Nov 28, 2011||End Date/Time: Dec 10, 2011|
The must-attend forum for drug and diagnostic developers is back. The World Companion Diagnostics Summit has been designed by leading biomarker and companion diagnostics specialists at Roche, Novartis, Johnson & Johnson, GSK, Merck, AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer and many more to assist you in turning biomarker research into successful patient stratification and to deliver better, safer drugs to market with drug-diagnostic co-development.
With all the fascinating feedback weâ€™ve heard from you over the last few months, weâ€™re putting together an agenda this year thatâ€™s packed with fresh, new insights and that addresses the most up-to-date issues and challenges in drug-diagnostic co-development.
So whatâ€™s on the agenda?
Key topics that have emerged this year that people really want to hear about are:
â€¢ The different CDx strategies companies are taking, both in large pharma and smaller drug developing companies: How are they going about trying to stratify patient populations? E.g. In-house development vs. outsourcing? LDT vs. IVD? Prospective vs. retrospective biomarker development?
â€¢ Who has run or is looking to prospectively run their clinical trial based on their biomarker? Who has retrospectively identified a biomarker that they are now integrating into clinical trials for patient stratification, including post-market approval?
â€¢ What does the regulatory and reimbursement landscape of CDx development look like?
â€¢ How do we ensure a CDx product gets on to the market and achieves return on investment?
â€¢ How do we translate biomarkers from the laboratory to the clinic and achieveassay validation?
â€¢ What are the partnering options and opportunities for CDx? How do webalance the risk and reward of CDx development by structuring partnership deals for mutual benefit?
â€¢ When is the best time to partner?
â€¢ What are the latest tools and technologies that could have an impact on patient stratification? E.g. next-generation sequencing, point of care diagnostics, multiplex assays based on biosignatures etc.
â€¢ How do we ensure access to clinical samples needed for biomarker identification and CDx development?
These topics will form the core of this yearâ€™s agenda.
To register simply:
Call: +44 20 3141 8700
Please quote the booking code: LIST when registering to secure your place at the meeting.